6/19/2013

The European Medicines Agency has approved the use of Celgene's Revlimid, or lenalidomide, in some myelodysplastic syndromes patients. The approval covers the use of the drug in patients with low- or intermediate-1-risk myelodysplastic syndrome and deletion 5q chromosomal abnormalities but no other chromo­somal ab­nor­mali­ties and who have become dependent on red blood cell transfusions and are not responding to other treatments.

Full Story:
MDSBeacon.com

Related Summaries